Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses
暂无分享,去创建一个
C. Brander | N. Frahm | A. McMichael | M. McElrath | G. Ferrari | G. Tomaras | T. Hanke | N. Goonetilleke | B. Mothe | L. Dorrell | D. Chopera | Alyse L Frisbee | G. Hancock | Hongbing Yang | Elisabeth Yorke | E. Wainwright | Victoria Bourne | Tamika L. Payne | Mark Berrong | Alyse L. Frisbee | Citation Hancock | Yang H | Yorke E | Wainwright E Bourne | Frisbee A | David T Evans | G. Ferrari
[1] B. Walker,et al. HIV Molecular Immunology 2014 , 2015 .
[2] D. Heckerman,et al. Emergence of Individual HIV-Specific CD8 T Cell Responses during Primary HIV-1 Infection Can Determine Long-Term Disease Outcome , 2014, Journal of Virology.
[3] David Heckerman,et al. HIV Control Is Mediated in Part by CD8+ T-Cell Targeting of Specific Epitopes , 2014, Journal of Virology.
[4] S. Shapiro. Clinical development of candidate HIV vaccines: different problems for different vaccines. , 2014, AIDS research and human retroviruses.
[5] J. Excler,et al. Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults , 2014, PloS one.
[6] Lucy Dorrell,et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] J. Mullins,et al. Altered Response Hierarchy and Increased T-Cell Breadth upon HIV-1 Conserved Element DNA Vaccination in Macaques , 2014, PloS one.
[8] Holly Janes,et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.
[9] R. Koup,et al. Differential Impact of Magnitude, Polyfunctional Capacity, and Specificity of HIV-Specific CD8+ T Cell Responses on HIV Set Point , 2013, Journal of Virology.
[10] N. Frahm,et al. Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. , 2013, The Journal of infectious diseases.
[11] N. Loman,et al. Extreme genetic fragility of the HIV-1 capsid , 2013, Retrovirology.
[12] Matthew S. Lewis,et al. Immune clearance of highly pathogenic SIV infection , 2013, Nature.
[13] Morgane Rolland,et al. Fitness Costs of Mutations at the HIV-1 Capsid Hexamerization Interface , 2013, PloS one.
[14] T. Hertz,et al. HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1 , 2013, PLoS pathogens.
[15] B. Angus,et al. Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection. , 2013, Journal of immunological methods.
[16] Matthew S. Lewis,et al. Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms , 2013, Science.
[17] C. Rouzioux,et al. CD8 T-Cells from Most HIV-Infected Patients Lack Ex Vivo HIV-Suppressive Capacity during Acute and Early Infection , 2013, PloS one.
[18] D. Heckerman,et al. HIV-1 p24gag Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice , 2013, PloS one.
[19] P. Doherty,et al. Preemptive priming readily overcomes structure-based mechanisms of virus escape , 2013, Proceedings of the National Academy of Sciences.
[20] Dylan H. Westfall,et al. HIV-1 Conserved-Element Vaccines: Relationship between Sequence Conservation and Replicative Capacity , 2013, Journal of Virology.
[21] David Heckerman,et al. Frequent and Variable Cytotoxic-T-Lymphocyte Escape-Associated Fitness Costs in the Human Immunodeficiency Virus Type 1 Subtype B Gag Proteins , 2013, Journal of Virology.
[22] Feng Gao,et al. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. , 2012, The Journal of clinical investigation.
[23] Anuska Llano,et al. Best-Characterized HIV-1 CTL Epitopes: The 2013 Update , 2013 .
[24] A. McMichael,et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. , 2012, The Journal of infectious diseases.
[25] Bette Korber,et al. Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys , 2012, Journal of Virology.
[26] H. Ding,et al. Initial HIV-1 Antigen-Specific CD8+ T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus Replication , 2012, Journal of Virology.
[27] J. Blankson,et al. Inhibitory Potential of Subpopulations of CD8+ T Cells in HIV-1-Infected Elite Suppressors , 2012, Journal of Virology.
[28] D. Heckerman,et al. CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control , 2012, PloS one.
[29] Todd M. Allen,et al. Definition of the viral targets of protective HIV-1-specific T cell responses , 2011, Journal of Translational Medicine.
[30] Alan S. Perelson,et al. Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection , 2011, Journal of Virology.
[31] J. Kublin,et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. , 2011, The Lancet. Infectious diseases.
[32] B. Korber,et al. Mapping HIV-1 Vaccine Induced T-Cell Responses: Bias towards Less-Conserved Regions and Potential Impact on Vaccine Efficacy in the Step Study , 2011, PloS one.
[33] Matthew S. Lewis,et al. Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.
[34] B. Korber,et al. Correction: Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine , 2011, PLoS ONE.
[35] Peter B. Gilbert,et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the Step trial , 2011, Nature Medicine.
[36] N. Frahm,et al. Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles , 2011, PLoS pathogens.
[37] K. Järvelin. Evaluation , 2008, Interactive Information Seeking, Behaviour and Retrieval.
[38] S. Buus,et al. Efficacious Early Antiviral Activity of HIV Gag- and Pol-Specific HLA-B*2705-Restricted CD8+ T Cells , 2010, Journal of Virology.
[39] M. Carrington,et al. Enhanced Anti-HIV Functional Activity Associated with Gag-Specific CD8 T-Cell Responses , 2010, Journal of Virology.
[40] J. Kappes,et al. Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination , 2010, Journal of Virology.
[41] B. Walker,et al. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. , 2010, The Journal of infectious diseases.
[42] Bette Korber,et al. Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys , 2010, Nature Medicine.
[43] Alan S. Perelson,et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection , 2009, The Journal of experimental medicine.
[44] Tulio de Oliveira,et al. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences , 2009, Nucleic Acids Res..
[45] Anthony D. Kelleher,et al. Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4+ T Cells , 2009, Journal of Virology.
[46] Norman L. Letvin,et al. T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces , 2009, Journal of Virology.
[47] D. Watkins,et al. Vaccine-Induced Cellular Responses Control Simian Immunodeficiency Virus Replication after Heterologous Challenge , 2009, Journal of Virology.
[48] Bin Li,et al. HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition , 2008, Journal of Virology.
[49] Donald K Carter,et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.
[50] Devan V Mehrotra,et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.
[51] David Heckerman,et al. Marked Epitope- and Allele-Specific Differences in Rates of Mutation in Human Immunodeficiency Type 1 (HIV-1) Gag, Pol, and Nef Cytotoxic T-Lymphocyte Epitopes in Acute/Early HIV-1 Infection , 2008, Journal of Virology.
[52] Todd M. Allen,et al. Antigen Load and Viral Sequence Diversification Determine the Functional Profile of HIV-1–Specific CD8+ T Cells , 2008, PLoS medicine.
[53] James I Mullins,et al. HIV-1 Group M Conserved Elements Vaccine , 2007, PLoS pathogens.
[54] Bette Korber,et al. Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine , 2007, PloS one.
[55] Jacques Fellay,et al. A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1 , 2007, Science.
[56] A. McMichael,et al. Broad TCR Usage in Functional HIV-1-Specific CD8+ T Cell Expansions Driven by Vaccination during Highly Active Antiretroviral Therapy1 , 2007, The Journal of Immunology.
[57] Zoe Moodie,et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. , 2007, Journal of immunological methods.
[58] Asier Sáez-Cirión,et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype , 2007, Proceedings of the National Academy of Sciences.
[59] David Heckerman,et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.
[60] Peter B Gilbert,et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. , 2006, Vaccine.
[61] Mario Roederer,et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.
[62] S. Rowland-Jones,et al. Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag Vaccine , 2006, Journal of Virology.
[63] Bette T. Korber,et al. Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control , 2006, Journal of Virology.
[64] Tulio de Oliveira,et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..
[65] D. Ho,et al. Isolation and Quantitation of HIV in Peripheral Blood , 1993, Current protocols in immunology.
[66] A. McMichael,et al. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. , 2000, Nature Medicine.
[67] G. Ferrari,et al. CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[68] D. Montefiori,et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.
[69] D. Ho,et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.
[70] A. Williamson,et al. Use of sulforaphane in COVID-19: Clinical trials are needed , 2022, Molecular Immunology.